-
Product Insights
Pulmonary Arterial Hypertension - Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Pulmonary Arterial Hypertension - Global Clinical Trials Review, 2026" provides an overview of Pulmonary Arterial Hypertension Clinical trials scenario. This report provides top line data relating to the clinical trials on Pulmonary Arterial Hypertension. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Sector Analysis
Pulmonary Arterial Hypertension Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034
This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the Pulmonary Arterial Hypertension market through 2034. GlobalData estimated that drug sales for PAH in 2024 were approximately $7.65 billion across the 7MM. With an estimated $5.83 billion in drug sales in 2024, the US dominated the PAH market, contributing 76.3% of the sales in the 7MM. This high market share is primarily due to the large PAH prevalent population and...
-
Sector Analysis
Pulmonary Arterial Hypertension in 68-Markets: Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2034
This report covers the 68 geographical markets and provides an Excel-based forecast model for the Pulmonary Arterial Hypertension market. Across the 68 markets, sales in the PAH market were $10.1 billion in 2024, growing to $17.9 billion in 2034. The seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) represent approximately 24.5% and 48.0% in 68-market sales in 2024 and 2034, respectively.
-
Sector Analysis
Pulmonary Arterial Hypertension (PAH) Epidemiology Analysis and Forecast to 2034
Pulmonary arterial hypertension (PAH) is a rare, progressive disorder of unknown cause, characterized by vascular proliferation and remodelling of the small pulmonary arteries. A significant number of risk factors and pathophysiological conditions are suspected to play roles in disease progression (Humbert et al., 2004, 2010; Simonneau et al., 2004; Bonnet et al., 2017). In PAH, blood vessels in the lungs are narrowed, blocked, or destroyed. The damage slows blood flow through the lungs and can lead to right ventricular overload...
-
Product Insights
Pulmonary Hypertension - Drugs In Development, 2024
Empower your strategies with our Pulmonary Hypertension – Drugs In Development, 2024 report and make more profitable business decisions. Pulmonary hypertension (PH) is a rare condition marked by high blood pressure in the pulmonary arteries, which supply blood to the lungs. It can stem from various causes, including heart or lung diseases. PH leads to arterial narrowing, forcing the heart to work harder, potentially resulting in heart failure. Common symptoms include breathlessness, fatigue, chest pain, and dizziness. Management involves medication, oxygen...
-
Product Insights
Pulmonary Arterial Hypertension - Drugs In Development, 2024
Empower your strategies with our Pulmonary Arterial Hypertension – Drugs In Development, 2024 report and make more profitable business decisions. Pulmonary arterial hypertension (PAH) is a type of high blood pressure that occurs in the right side of the heart and in the arteries that supply blood to the lungs. Symptoms include chest pain, fatigue, passing out suddenly, and swelling of the legs (edema). Risk factors include family history, age, obesity, obstructive sleep apnea, and other diseases, including congenital heart disease,...
-
Product Insights
Chronic Thromboembolic Pulmonary Hypertension - Drugs In Development, 2024
Empower your strategies with our Chronic Thromboembolic Pulmonary Hypertension – Drugs In Development, 2024 report and make more profitable business decisions. Chronic thromboembolic pulmonary hypertension (CTEPH) also called as Chronic pulmonary embolism, is a pulmonary vascular disease caused by chronic block of the major lung arteries. It is the major cause of chronic PH leading to right heart failure and death. The Chronic Thromboembolic Pulmonary Hypertension drugs in development market research report provide comprehensive information on the therapeutics under development for...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.